Table 2.
Prevalence of tfs3 ICE T4SS genes in DU, NCGC, and CG.
| DU (%), n = 46 | NCGC (%), n = 51 | CG (%), n = 39 | Total (%), n = 136 | |
|---|---|---|---|---|
| virB2 | 15 (32.6) | 11 (21.5) | 10 (25.6) | 36 (26.4) |
| virB3 | 15 (32.6) | 11 (21.5) | 10 (25.6) | 36 (26.4) |
| virB4 | 15 (32.6) | 11 (21.5) | 10 (25.6) | 36 (26.4) |
| virB6 | 18 (39.1) | 14 (27.4) | 13 (33.3) | 45 (33.0) |
| virB7 | 16 (34.7) | 9 (17.6) | 7 (17.9) | 32 (23.5) |
| virB8 | 15 (32.6) | 9 (17.6) | 7 (17.9) | 31 (22.8) |
| virB9 | 17 (36.9) | 10 (19.6) | 7 (17.9) | 34 (25.0) |
| virB10 | 17 (36.9) | 10 (19.6) | 7 (17.9) | 34 (25.0) |
| virB11 | 16 (34.8) | 11 (21.5) | 7 (17.9) | 34 (25.0) |
| virD4 | 16 (34.8) | 11 (21.5) | 7 (17.9) | 34 (25.0) |
| virD2 | 19 (41.3) | 10 (19.6) | 15 (38.4) | 44 (32.3) |
| xerT | 21 (45.6) | 20 (39.2) | 18 (46.1) | 59 (43.3) |
| ctkA | 14 (30.4) | 15 (29.4) | 10 (25.6) | 39 (28.6) |
| Incomplete tfs3 | 9 (19.5) | 15 (30.0) | 13 (33.3) | 37 (27.2) |
| Complete tfs3 | 14b (30.4) | 6 (11.7) | 5 (12.8) | 25 (18.4) |
| Complete tfs3 and ctkA | 7 (15.2) | 5 (9.8) | 1 (2.5) | 12 (8.8) |
| Incomplete tfs3 and cagPAI | 9 (19.5) | 13 (25.5) | 11 (28.2) | 33 (24.3) |
| Complete tfs3 and cagPAI | 13a,b (28.2) | 5 (9.8) | 3 (7.7) | 21 (15.4) |
aIndicated significant difference in prevalence between DU and CG at P < 0.05.
bIndicated significant difference in prevalence between DU and NCGC at P < 0.05.